tbuckley/cabot-search huggingface dataset:
Volatile N-Nitrosamine Formation after Intake of Nitrate at the ADI Level in Combination with an Amine-Rich Diet
Authors: Ingrid T. M. Vermeer, Danielle M. F. A. Pachen, Jan W. Dallinga, Jos C. S. Kleinjans, Jan M. S. van Maanen
Journal: Environmental Health Perspectives (1998)

The principles of quantitative structure-activity relationships (QSAR) are based on the premise that the properties of a chemical are implicit in its molecular structure. Therefore, if a mechanistic hypothesis can be proposed linking a group of related chemicals with a particular toxic end point, the hypothesis can be used to define relevant parameters to establish a QSAR. Ways in which QSAR and in vitro toxicology can complement each other in development of alternatives to live animal experiments are described and illustrated by examples from acute toxicological end points. Integration of QSAR and in vitro methods is examined in the context of assessing mechanistic competence and improving the design of in vitro assays and the development of prediction models. The nature of biological variability is explored together with its implications for the selection of sets of chemicals for test development, optimization, and validation. Methods are described to support the use of data from in vivo tests that do not meet today's stringent requirements of acceptability. Integration of QSAR and in vitro methods into strategic approaches for the replacement, reduction, and refinement of the use of animals is described with examples.
Use of Colorectal Cancer Tests—United States, 2002, 2004, and 2006
Journal: JAMA (2008)

Colorectal cancer is the second-leading cause of cancer-related deaths in the United States among cancers that affect both men and women. The U.S. Preventive Task Force and other national organizations recommend that persons aged > or =50 years at average risk be screened for colorectal cancer using one or more of the following methods: fecal occult blood testing (FOBT) every year, sigmoidoscopy or double-contrast barium enema every 5 years, or colonoscopy every 10 years. To estimate rates of use of colorectal cancer tests and to evaluate changes in test use, CDC compared data from the 2002, 2004, and 2006 Behavioral Risk Factor Surveillance System (BRFSS) surveys. This report describes the results of that comparison, which indicated that the proportion of respondents aged > or =50 years reporting use of FOBT and/or sigmoidoscopy or colonoscopy increased overall from 2002 to 2006; however, certain populations, such as racial/ethnic minorities and those who reported no health insurance coverage, had lower prevalence of testing. Specific measures to increase colorectal cancer screening and address disparities in screening are needed.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009
Authors: T. A. Dolecek, J. M. Propp, N. E. Stroup, C. Kruchko
Journal: Neuro-Oncology (2012)

primary brain and CNS tumors in the United States.This report represents a dramatic increase in population coverage (approximately 97% from the initial CBTRUS Reports).The central cancer registries receive populationbased, standardized data from all healthcare data sources primarily through certified tumor registrars.Along with the UDS, there are quality control checks and a system for rating each central registry to further insure that these data are reported as accurately and completely as possible.These individuals and organizations provide the high quality data that are the foundation of the CBTRUS statistical reports and scientific activities.This statistical report continues the past efforts that CBTRUS has made to provide population-based incidence rates for all primary brain and CNS tumors by histology, age, gender, race, and Hispanic ethnicity.As in previous reports, these data have been organized by clinically relevant histological groupings that are useful for surveillance.The information is important for allocation and planning of specialty health -care services, in the planning of disease prevention and control programs, and in research activities.These data may lead to clues that will stimulate research into the causes of this terrible disease.In 2012, the CBTRUS staff in collaboration with three neuropathologists, Drs.
Clinical Pathological Conference. Progressive personality changes and hemiparesis in a middle-aged man
Journal: JAMA (1973)

<h3>Dr. Tarsy:</h3> A 46-year-old, right-handed drawbridge operator was admitted to the Boston Veterans Administration Hospital on July 27, 1970, because of personality changes of six months' duration and mild left hemiparesis of three months' duration. Six months earlier, he had had several minor automobile accidents, which were apparently due to inattention. In addition, because of repeated errors, one month prior to admission he had been forced to resubmit reports detailing ship passages beneath the drawbridge he operated. The patient's family had noted a decline in motivation; he became irritable as well and oblivious to criticism concerning his behavior. On the day of admission, he urinated against the front wall of the hospital. There was no history of memory loss, geographic disorientation, or difficulty with speech, but he did have a three-month history of drooping of the left corner of his mouth and diminished dexterity in his left hand.
Francis Crick
Authors: Sara L. Tobin
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MADRID
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Body Size and Vertebral Fractures
Authors: Karen L. Margolis, Kristine E. Ensrud
Journal: Annals of Internal Medicine (2001)

Letters1 May 2001Body Size and Vertebral FracturesKaren L. Margolis, MD, MPH and Kristine E. Ensrud, MD, MPHKaren L. Margolis, MD, MPHHennepin County Medical Center; Minneapolis, MN 55415 (Margolis)Minneapolis Veterans Affairs Medical Center; Minneapolis, MN 55417 (Ensrud)Search for more papers by this author and Kristine E. Ensrud, MD, MPHHennepin County Medical Center; Minneapolis, MN 55415 (Margolis)Minneapolis Veterans Affairs Medical Center; Minneapolis, MN 55417 (Ensrud)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-9_Part_1-200105010-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Blank notes that DXA is not a volumetric measurement of BMD. He cites evidence that BMD of the lumbar vertebrae as measured by DXA is correlated with height and weight, whereas volumetric BMD measurements are not (1). He suggests that this may explain our finding that the associations between larger body size and risks for hip, pelvis, and rib fractures are eliminated by adjustment for hip BMD since DXA measurement captures bone size as well as BMD.To test this hypothesis, we did additional proportional hazards analyses of the associations between total body weight and risks for ...References1. Jergas M, Breitenseher M, Gluer CC, Yu W, Genant HK. Estimates of volumetric bone density from projectional measurements improve the discriminatory capability of dual X-ray absorptiometry. J Bone Miner Res. 1995;10:1101-10. [PMID: 0007484286] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Karen L. Margolis, MD, MPH; Kristine E. Ensrud, MD, MPHAffiliations: Hennepin County Medical Center; Minneapolis, MN 55415 (Margolis)Minneapolis Veterans Affairs Medical Center; Minneapolis, MN 55417 (Ensrud) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBody Size and Risk for Clinical Fractures in Older Women Karen L. Margolis , Kristine E. Ensrud , Pamela J. Schreiner , and Holly K. Tabor , for the Study of Osteoporotic Fractures Research Group*Body Size and Vertebral Fractures Robert D. Blank Body Size and Vertebral Fractures Robert D. Blank Metrics 1 May 2001Volume 134, Issue 9_Part_1Page: 796KeywordsBone mineral densityDual energy x ray absorptiometryEstrogensExerciseFallsHipHip fracturesOdds ratioPelvisRibs ePublished: 1 May 2001 Issue Published: 1 May 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
Authors: Ramona Schulz, Natalia D. Marchenko, Lena Holembowski, Günter Fingerle-Rowson, Marina Pesic, Lars Zender, Matthias Dobbelstein, Ute M. Mol
Journal: The Journal of Experimental Medicine (2012)
QOL-53. GENOME ASSOCIATIONS WITH NEUROCOGNITIVE OUTCOMES, CEREBRAL MICROBLEEDS (CMBS), AND BRAIN VOLUME AND WHITE MATTER (WM) CHANGES IN PEDIATRIC BRAIN TUMOR SURVIVORS
Authors: Cassie Kline, Schuyler Stoller, Lennox Byer, Caleb Edwards, Rachna Prasad, Joseph Torkildson, Karen Gauvain, David Samuel, Janine Lupo, Melanie Morrison, Elizabeth Tong, Solomiia Savchuk, Christian Rodrigo Ugaz Valencia, Andreas Rauschecker, Jeffrey Rudie, Thomas Hoffman, Dena Dubal, Heather Fullerton, Sabine Mueller
Journal: Neuro-Oncology (2020)

Abstract OBJECTIVE To identify genetic predictors of neurocognition, CMBs, brain volume, and WM changes in pediatric brain tumor survivors. METHODS Patients were selected from an existing cohort (RadART) if they had: 1) at least one neurocognitive evaluation using computer-based CogState; 2) available DNA; 3) standard imaging. Candidate gene or genome-wide genotyping was performed on all patients. CMBs were identified using a semi-automated algorithm developed in MATLAB. Volume of T2/FLAIR WM signal abnormality was measured using a semi-automated method based on a convolutional neural network. Brain volume and cortical thickness were measured using FreeSurfer volumetric analysis. Logistic and linear regression were done to compare phenotypes with candidate genotypes. Genome-wide efficient mixed-model analysis was done to compare neurocognition and CMBs. Gene set analysis was done using https://fuma.ctglab.nl/. RESULTS APOE4 was a candidate variant associated with non-lobar, larger volume CMBs (p&amp;lt;0.05). At the GWAS-level (n=225), specific genes trended with visual memory, psychomotor function, and CMB count (p&amp;lt;5x10-8). Using gene set analyses, there were gene set trends seen with CMB count and psychomotor function. Small sample size and low mutant allele frequency limited reliability of these findings. Preliminary volumetric analysis show reduced volume within the right parietal, medial occipital and inferior temporal lobes with increased cortical thickness in the left occipital and medial parietal lobe in patients carrying the ApoE4 allele. WM signal assessments are ongoing. CONCLUSION Genetic markers may be associated with neurocognition, CMBs, brain volume and WM changes in pediatric brain tumor survivors; however, larger cohorts are needed to confirm specific gene relevance.
Kiss of Death
Journal: New England Journal of Medicine (2011)

361:807-16).In the Pathological Discussion (page 815), the penultimate paragraph, which currently begins with "Damage to the liver . . .," should be corrected as follows: The final sentence, which begins, "The pancreas was atrophic," should instead appear at the beginning of the paragraph and should cite Figure 4C, not 4D.In the sentence that begins, "In this case," the two parenthetical figure citations should be "(Fig.4D)" and "(Fig.4D, inset)," rather than "(Fig.4C)" and "(Fig.4C, inset)."The article is correct at NEJM.org.(June 11, 2009;360:2564-8).In the Commentary (page 2567), the parenthetical in the final sentence of the third paragraph, "(e.g., intravenous immune globulin for hepatitis A infection)," should be deleted, so that the sentence reads, "The treatment of other viral infections is generally not initiated until a specific diagnosis has been made."The article is correct at NEJM.org. Kiss of Death
Induction of Hepatocellular Carcinoma in Nonhuman Primates by the Food Mutagen 2-Amino-3-Methylimidazo[4,5-f]quinoline
Authors: Richard H. Adamson, Shozo Takayama, Takashi Sugimura, Unnur P. Thorgeirsson
Journal: Environmental Health Perspectives (1994)

The heterocyclic aromatic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) was evaluated for carcinogenic effects in macaques, primarily cynomolgus monkeys. IQ was administered by gavage five times a week at doses of 10 or 20 mg/kg. IQ induced hepatocellular carcinoma in 55% of the animals at the low dose and in 95% of the animals at 20 mg/kg. The average latent period at the high dose level was 43 months and that at the low dose was 60 months. Generally, the tumor nodules exhibited a well- to moderately well-differentiated hepatocellular carcinoma, and a trabecular pattern was most frequently seen. Pulmonary metastases were also found in several of the monkeys. Thus, IQ is a potent carcinogen in nonhuman primates and is a potential carcinogen for humans.
Escherichia coli O157:H7 Outbreak at a Summer Camp—Virginia, 1994
Journal: JAMA (1995)

On August 8, 1994, the Virginia Department of Health was notified that several campers and counselors at a summer camp had developed bloody diarrhea. The outbreak began during the July 17-30 session at a rural camp where activities included frequent overnight trips at which meals were cooked over a campfire. This report summarizes the findings from the investigation, which confirmed E. coli O157:H7 as the causative agent.(ABSTRACT TRUNCATED AT 250 WORDS)
Book Review
Authors: Stjepan Betlheim, Duška Blažević, Oluf Brüel, R. Brun, A. Caruso, E.E. Krapf, A. Maeder, Berthold Stokvis, Erwin Stransky, M. Boss
Journal: Psychotherapy and Psychosomatics (1955)

Book Reviews -Buchbesprechungen -Livres Nouveaux III/1955 La signification du droit juvénile est circonscrite non seulem ent par le droit sur l'enfant mais également par le droit dû à l'enfant.Ce travail im portant et rem pli de nouvelles idées est destiné pour être lu par les psychiatres, les juristes, les sociologues et tous ceux participant grâce à leur m étier et leur vocation au jugem ent sur l'enfant délinquant ou bien défectueux dans son pouvoir d'adaptation sociale.
31st ESMO Congress – Officers and organization
Authors: Håkan Mellstedt, Haluk Onat, Hakan Akbulut, Ankara Nuri, F Aykan, Ibrahim Barista, Ankara Sevil, E Bavbek, Gökhan Demir, Istanbul Fikri Icli, Ankara Pinar, M Saip, Erdem Göker, Bornova Izmir, Necdet Üskent, Hans Schmoll, Fabrice André, France Baselga, Michael Spain, Michael Cullen, A Kosmidis, Hakan Greece, Sweden Mellstedt, Martine Onat, Gunta Belgium, Latvia Purkalne, Dirk Norway, Christos Belgium, Rolf Belgium
Journal: Annals of Oncology (2006)
Physician's guide to the Occupational Safety and Health Act of 1970
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
Authors: Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, Petra Langerbeins, Anna-Maria Fink, Thomas Illmer, Holger Klaproth, Sven Estenfelder, Matthias Ritgen, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
Journal: Blood (2016)
Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease
Authors: Elina Jerschow, Matthew Edin, Teresa Pelletier, Waleed Abuzeid, Nadeem Akbar, Marc Gibber, Marvin Fried, Fred B. Lih, Artiom Gruzdev, J. Alyce Bradbury, Weigup Han, Golda Hudes, Taha Keskin, Victor Schuster, Simon Spivack, Darryl Zeldin, David Rosenstreich
Journal: Journal of Allergy and Clinical Immunology (2017)
Serum levels of IFN- do not correlate with disease activity in patients with dermatomyositis/polymyositis
Authors: J. Vencovsky, P. Krol, O. Krystufkova, P. Polanska, H. Mann, M. Klein, O. Beran
Journal: Annals of the Rheumatic Diseases (2011)

<h3>Introduction</h3> Recent studies show an important role of type I interferon (IFN) in the proinflammatory process leading to disease manifestations in muscle tissue in patients with polymyositis (PM) and dermatomyositis (DM). <h3>Aim</h3> To investigate the relationship of soluble IFN-α serum levels with clinical and laboratory characteristics in patients with PM and DM. <h3>Methods</h3> Serum samples of 43 patients with DM (n=24) and PM (n=19) (32 females/11 males) were selected from a cohort of 81 PM/DM cases with the preference for those with anti-Jo-1 antibodies (n=26) and those with muscle MRI performed (n=22). IFN-α levels were measured using bead-based assay (human IFN-α FlowCytomix Simplex, Bender MedSystems,sensitivity 2.2 pg/ml). Clinical activities were assessed using the MYOACT tool. Degree of muscle oedema on STIR muscle MRI was used to measure local disease activity and evaluated using 10 cm visual analogue scale. Patients were either untreated (n=19), treated with prednisone at doses ≤20 mg (n=15), or &gt;20 mg per day (n=9) at the time of blood collection. Healthy subjects (n=25) and patients with viral infection (n=6) were used as controls. <h3>Results</h3> Significantly lower levels of IFN-α were found in sera of myositis patients in comparison with controls. No difference was noted between patients who were untreated, or treated with low or high prednisone. IFN-α levels were significantly higher in anti-Jo-1 positive patients (median 117.8 pg/ml, range 70–378) in comparison with anti-Jo1 negative (median 93.4 pg/ml, range 0–199) (p=0.05). There were no significant differences in IFN-α levels between PM and DM patients. Significant negative correlation was found between IFN-α and the intensity of MRI signal. None of the clinical or laboratory parameters as assessed by MYOACT showed any correlation with IFN-α levels, with the exception of the tendency to higher IFN-α levels (p=0.064) in the presence of interstitial lung disease. <h3>Conclusion</h3> Serum levels of IFN-α in patients with PM and DM were lower compared to controls. This is not a consequence of the treatment since the levels of IFN-α were not different in patients tested before or during therapy. Serum levels of IFN-α do not seem to be an indicator of clinical activity; the lower the serum level the more severe the muscle oedema, as demonstrated by the intensity parameter on MRI. This could indicate rather local than systemic effect of IFN-α. Alternatively, other type I interferons and not the IFN-α may be responsible for the type I IFN signature that is characteristic for many DM and PM patients.
Thyrotoxicosis
Authors: Philip R. Alper
Journal: JAMA (1970)

<h3>To the Editor.—</h3> The article on "T<sub>3</sub>Thyrotoxicosis" by Sterling et al (<b>213</b>:571, 1970) illustrates a disease that is probably considerably more frequent than previously appreciated. Because of the relatively greater metabolic potency of triiodothyronine (T<sub>3</sub>), than thyroxine (T<sub>4</sub>), a thyroid gland that produced a relatively larger quantity of the former than normal would produce a hypermetabolic state in which proteinbound iodine (PBI) or serum T<sub>4</sub>level, T<sub>3</sub>uptake, and radioactive iodine uptake might all be within normal limits. By this simple metabolic alteration, thyroid hyperplasia would not even be necessary to produce a hypermetabolic state. Since hyperthyroidism has long been known to be a remittent disease, the question of whether remission represents a relative change in the production of T<sub>3</sub>vs T<sub>4</sub>rather than total thyroidal activity must be asked. Although there is a rough correlation between the level of serum T<sub>4</sub>and